title: Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.
abstract: Although live attenuated vaccine strains of simian immunodeficiency virus (SIV) have proven highly effective in protecting macaques against challenge with pathogenic SIV strains, little is known about the mechanisms of protective immunity induced by these vaccines. We examined cytotoxic T-lymphocyte (CTL) responses against SIV in animals infected with SIVmac239delta nef (deficient in nef) or SIVmac239delta 3 (deficient in nef, vpr, and upstream sequences in U3). To enhance detection of SIV-specific CTL activity, we stimulated peripheral blood mononuclear cells with autologous B-lymphoblastoid cell lines which had been infected with recombinant vaccinia viruses expressing SIV proteins and subsequently inactivated with psoralen and UV light. Animals chronically infected with SIV239delta nef or SIV239delta 3 mounted vigorous CTL responses against the SIV Gag and Env proteins. This CTL activity was major histocompatibility class restricted and mediated by CD8+ T lymphocytes. CTL responses persisted at relatively high levels for more than 6 years after infection. Limiting dilution precursor frequency assays demonstrated that the frequency of SIV-specific CTLs was as high as 234 CTL precursors per 100,000 cells. Animals acutely infected with SIV239delta nef developed CTL activity by day 14 after infection, coincident with decreases in viral load. Animals acutely infected with SIV239delta 3 developed CTL responses within 4 weeks of infection. Thus, vaccination of juvenile or adult animals with SIV239delta nef or SIV239delta 3 results in the induction of a vigorous CTL response which arises early in the course of infection and persists for years after a single inoculation of virus.
authors.affiliation: Division of Immunology, New England Regional Primate Research Center, Harvard Medical School, Southborough, Massachusetts 01772, USA. pjohnson@warren.med.harvard.edu
authors.forename: R P
authors.initials: RP
authors.lastname: Johnson
authors.forename: R L
authors.initials: RL
authors.lastname: Glickman
authors.forename: J Q
authors.initials: JQ
authors.lastname: Yang
authors.forename: A
authors.initials: A
authors.lastname: Kaur
authors.forename: J T
authors.initials: JT
authors.lastname: Dion
authors.forename: M J
authors.initials: MJ
authors.lastname: Mulligan
authors.forename: R C
authors.initials: RC
authors.lastname: Desrosiers
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation; D001402:B-Lymphocytes; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D002460:Cell Line; D002469:Cell Separation; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D007700:Kinetics; D008213:Lymphocyte Activation; D008253:Macaca mulatta; D018449:SAIDS Vaccines; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000821:virology; D013997:Time Factors; D014613:Vaccines, Attenuated
chemical_list: D000914:Antibodies, Viral; D018449:SAIDS Vaccines; D014613:Vaccines, Attenuated